Skip to main content

Development of Impentri, an intravenous imatinib formulation for Covid-19 acute respiratory distress syndrome (ARDS).

Project description

Repurposing imatinib for the treatment of severe pneumonia in COVID-19 patients

Field of science

  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /medical and health sciences/health sciences/infectious disease/RNA virus/coronavirus

Call for proposal

H2020-JTI-IMI2-2020-21-single-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

EXVASTAT LTD
Address
5 Tenison Avenue
CB1 2DX Cambridge
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 536 600,50

Participants (4)

STICHTING VUMC
Netherlands
EU contribution
€ 1 091 880
Address
De Boelelaan 1117
1081 HV Amsterdam
Activity type
Research Organisations
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 783 192,50
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
K.A.B.S. LABORATORIES INC. - KABS
Canada
EU contribution
€ 438 376,25
Address
De Tonnanancour 4500
J3Y 9G2 St-hubert
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ORION SANTE SARL
France
EU contribution
€ 812 913,75
Address
Centre D Affaires Le Boursidere Bat 1E Jura Bp 141
92357 Le Plesiss Robinson
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)